14-day Premium Trial Subscription Try For FreeTry Free
$0.385
-0.0020 (-0.517%)
At Close: May 02, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.315 $0.440 Thursday, 2nd May 2024 GLMD stock ended at $0.385. This is 0.517% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 5.56% from a day low at $0.378 to a day high of $0.399.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
May 04, 2023 $0.310 $0.310 $0.291 $0.300 26 944
May 03, 2023 $0.320 $0.320 $0.301 $0.310 32 260
May 02, 2023 $0.300 $0.312 $0.295 $0.300 31 123
May 01, 2023 $0.309 $0.310 $0.290 $0.290 26 697
Apr 28, 2023 $0.300 $0.310 $0.300 $0.310 74 666
Apr 27, 2023 $0.320 $0.320 $0.300 $0.300 32 084
Apr 26, 2023 $0.320 $0.327 $0.300 $0.305 76 040
Apr 25, 2023 $0.330 $0.331 $0.306 $0.310 65 050
Apr 24, 2023 $0.319 $0.332 $0.309 $0.318 26 246
Apr 21, 2023 $0.320 $0.338 $0.315 $0.337 24 113
Apr 20, 2023 $0.340 $0.340 $0.308 $0.332 21 220
Apr 19, 2023 $0.349 $0.349 $0.323 $0.330 34 563
Apr 18, 2023 $0.325 $0.347 $0.325 $0.340 48 449
Apr 17, 2023 $0.301 $0.330 $0.300 $0.317 45 981
Apr 14, 2023 $0.325 $0.330 $0.300 $0.310 35 350
Apr 13, 2023 $0.310 $0.325 $0.305 $0.320 48 555
Apr 12, 2023 $0.310 $0.326 $0.300 $0.300 89 181
Apr 11, 2023 $0.339 $0.339 $0.300 $0.315 96 109
Apr 10, 2023 $0.370 $0.370 $0.330 $0.340 157 127
Apr 06, 2023 $0.357 $0.361 $0.340 $0.340 93 484
Apr 05, 2023 $0.354 $0.357 $0.340 $0.340 15 129
Apr 04, 2023 $0.320 $0.370 $0.310 $0.365 304 859
Apr 03, 2023 $0.450 $0.450 $0.310 $0.350 204 979
Mar 31, 2023 $0.444 $0.463 $0.419 $0.427 22 933
Mar 30, 2023 $0.460 $0.470 $0.380 $0.470 30 540
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT